The psoriasis market is about to get even more crowded.

Yesterday, Johnson & Johnson's (NYSE:JNJ) subsidiary Centocor announced positive phase 3 data for its psoriasis drug, Ustekinumab, at a scientific meeting in Argentina. More than two thirds of the patients who received the drug experienced up to a 75% reduction in psoriasis. Given the strong results from the trial, the company plans to file a marketing application for the drug by the end of the year.

If it's approved, the drug should be able to compete well on the market because it is easier to take than other drugs -- patients could inject it every 12 weeks. J&J's current treatment for psoriasis, Remicade, is given every eight weeks and requires a two-hour office visit for an IV. Amgen's (NASDAQ:AMGN) Enbrel is also self-injectable but has to be given weekly in its maintenance phase and twice weekly in the start-up phase.

By the time Ustekinumab is approved, the treatment choices could include another. Abbott Laboratories' (NYSE:ABT) is waiting to hear from the FDA about its label-expanding application for its anti-inflammation drug, Humira, for treating psoriasis.

The company also shouldn't discount potential competitors behind it in the clinic, such as Incyte's (NASDAQ:INCY) topical formation of its JAK inhibitor, which showed decent results in a recent phase 2 trial.

Ustekinumab is an antibody that blocks the cytokines interleukin 12 and interleukin 23, which normalize the immune response. Most anti-inflammation drugs work on several hyper-inflammation diseases -- rheumatoid arthritis and Crohn's disease, for example -- so I wouldn't be surprised if J&J tests it in other immune-mediated inflammatory diseases in the future.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.